Get Started
How GLP-1 Medications Work: Evidence & Safety | OptimalMD
Step 2 of 2   -   The science behind the program
Mechanism, Evidence & Safety

The Science, For Anyone Who Wants To Check Our Work.

How these medications actually work on your gut, pancreas and brain. Exactly which molecule you would be taking and how it relates to the brand names you have heard of. What the large clinical trials found, with the trial names and the numbers. And a straight account of the side effects, including the ones nobody puts in an ad.

Start With the Mechanism Back to Pricing & Program
18
Peer-reviewed trials and FDA labels cited
17,604
Adults in the largest cardiovascular trial
0
Claims made for the compounded product
Jump to any section
How they work in the body The two medications Clinical evidence Side effects & safety FAQ Full disclosures Step 1← Pricing & program
The Mechanism

What These Medications Actually Do In Your Body

GLP-1 medications are not appetite suppressants in the old sense, and they are not fat burners. They are engineered copies of a hormone your gut already makes after every meal - rebuilt to last about a week instead of a few minutes. Here is the physiology, step by step, including the parts researchers have not finished working out.

01

Where the signal startsA hormone you already make

GLP-1 is made mainly by L-cells in the lower small intestine and colon, and GIP by K-cells in the upper small intestine. Both are released in response to food. In healthy people, roughly half to two-thirds of the insulin released after a meal is driven by these gut hormones rather than by blood sugar alone, the so-called incretin effect. In type 2 diabetes, that effect is substantially blunted.

Your own GLP-1 breaks down within minutes. Semaglutide and tirzepatide are modified so they survive for days, which is what turns a fleeting mealtime signal into steady, week-long appetite regulation.

02

In the pancreasInsulin, but only when it's needed

These medicines increase insulin release only when blood sugar is elevated, and ease off as it normalizes. Crucially, the body's own emergency glucagon response is preserved if blood sugar drops too far.

That glucose-dependence is the reason low blood sugar is uncommon on these medications alone. The risk does rise when they are combined with insulin or a sulfonylurea, and those doses often need lowering - which is one of several reasons this is a prescription decision rather than a purchase.

03

In the stomachFood stays around longer

These medications slow how quickly the stomach empties, which contributes to feeling full for longer after a smaller meal and slows the rise in blood sugar after eating.

Worth knowing: this effect appears to lessen over months of treatment with the weekly medications, though it does not disappear entirely. While slowed emptying is one factor in nausea, researchers believe most of the appetite and nausea effects come from the brain rather than the stomach. Slowed emptying is also why you should tell any surgical or anesthesia team that you take one of these medications.

04

In the brainWhere appetite is actually set

This is where most of the effect happens. Rather than broadly crossing into the brain, these molecules reach it through specialized "windows" - regions near the brainstem and the base of the hypothalamus that lack the usual blood-brain barrier. From there the signal spreads to the circuits that govern hunger and fullness.

Many people describe something beyond simple appetite reduction, a quieting of the constant background preoccupation with food. Researchers are actively studying this, but there is not yet an agreed way to measure it, and exactly which brain circuits are responsible has not been fully mapped.

05

The second pathwayWhat tirzepatide adds: and the open question

Tirzepatide activates the GIP receptor alongside GLP-1, and it produces more weight loss than GLP-1 alone. Exactly why is still being worked out.

In a genuinely unusual twist, experimental drugs that block this same GIP receptor also produce substantial weight loss in trials. Both directions appear to work and the field has not reconciled why - there were formal point-counterpoint papers on this in 2025. Anyone who tells you the GIP mechanism is settled is ahead of the evidence.

06

DownstreamWhat changes once visceral fat comes off

Losing visceral and organ fat improves how your body responds to insulin, reduces fat stored in the liver, lowers markers of inflammation in the blood, modestly improves cholesterol and triglycerides, and produces a small reduction in blood pressure.

This is the part your lab work makes visible, and the reason your OptimalMD clinician orders biomarkers rather than judging progress by the scale alone.

Why the benefits may reach beyond weight loss

In the SELECT trial, the difference in heart outcomes began to appear within the first few months - before most participants had lost much weight, and before many had reached the full dose. A later prespecified analysis found the cardiovascular benefit was broadly similar regardless of how much weight a participant actually lost.

Researchers read this as a sign the medication helps through routes beyond fat loss alone. Which routes is still being investigated: reduced inflammation, effects on blood vessel function, changes in how the kidneys handle sodium, or some interaction among these. The honest summary is that the outcome benefits are well documented and the mechanisms behind them are still being characterized.

What You Would Actually Be Taking

Two Medications. Know What You're Taking.

Nearly every GLP-1 weight-loss brand you've heard of comes down to one of two active ingredients. Here is exactly what each one is, what it does, and how the version OptimalMD offers relates to the brand names.

GLP-1 Receptor Agonist

Semaglutide

A single-pathway medication that mimics GLP-1, the natural gut hormone your body releases after eating. It tells your brain you're full, slows how fast your stomach empties, and improves how your body handles blood sugar.

Same active ingredient as Ozempic® · Wegovy® · Rybelsus® - FDA-approved brand-name products from Novo Nordisk. The version offered through OptimalMD is compounded, prepared for an individual patient by a licensed compounding pharmacy. It is not FDA-approved, and it is not a generic or substitute version of any brand.
How it works
Activates the GLP-1 receptor, one hormone pathway.
How you take it
A once-weekly injection, or a once-daily oral tablet.
Trial results
In the branded trial of FDA-approved semaglutide 2.4 mg, average weight change was −14.9% at 68 weeks vs. −2.4% on placebo.
Deepest evidence
The largest body of outcome data of any GLP-1 - heart, kidney, liver, and joint trials.
Best suited to
People who want the most-studied option, prefer a lower entry price, or want an oral (no-needle) route.
See Semaglutide PricingThe evidence
Dual GIP + GLP-1 Agonist

Tirzepatide

A dual-pathway medication that activates two gut-hormone receptors instead of one - GLP-1 plus GIP. That second pathway is what makes it, in head-to-head testing, the more powerful option for weight loss.

Same active ingredient as Mounjaro® · Zepbound® - FDA-approved brand-name products from Eli Lilly. The version offered through OptimalMD is compounded, prepared for an individual patient by a licensed compounding pharmacy. It is not FDA-approved, and it is not a generic or substitute version of any brand.
How it works
Activates both GIP and GLP-1 receptors - two hormone pathways.
How you take it
A once-weekly injection.
Trial results
In the branded trial of FDA-approved tirzepatide, average weight change at the 15 mg dose was −20.9% at 72 weeks vs. −3.1% on placebo.
Head to head
In a 72-week trial comparing the two branded products directly, tirzepatide produced −20.2% vs. semaglutide's −13.7%.
Best suited to
People with a larger weight-loss goal, those who plateaued on semaglutide, or anyone with obesity plus sleep apnea.
See Tirzepatide PricingThe evidence

So which one should you take?

Tirzepatide produces more weight loss on average. Semaglutide has the deeper record for outcomes beyond the scale - cardiovascular, kidney, liver and joint benefits, and costs less to start. Neither is universally "better." Cost, tolerance, dosing preference, your medical history and your specific goal all matter.

That's the point of the clinician visit. Your OptimalMD provider reviews your history, current medications and goals, recommends a starting molecule and dose, and can change course if the first choice isn't the right fit.

The Science, Not the Hype

What These Molecules Do Beyond the Scale

The weight loss gets the headlines. The reason the medical community pays attention is what showed up in the large outcome trials - fewer heart attacks, slower kidney decline, better breathing, healthier livers, less joint pain. Here is the actual evidence, with the trial names and the numbers.

Please read this before the numbers below. Every trial on this page studied a branded, FDA-approved medication - Wegovy®, Ozempic®, Zepbound® or Mounjaro®, at a specific protocol dose, in a specific patient population. These results were not generated using compounded semaglutide or compounded tirzepatide, and they should not be read as a promise of what a compounded product will do for you. No clinical trial has established the safety or effectiveness of compounded versions. This section is education about the molecules themselves, not a claim about the products OptimalMD offers.
20%
Fewer major cardiac events
Semaglutide 2.4 mg vs. placebo in 17,604 adults with overweight/obesity and heart disease, over 3.3 years
24%
Fewer major kidney events
Semaglutide 1.0 mg vs. placebo in 3,533 adults with type 2 diabetes and chronic kidney disease
73%
Lower progression to diabetes
3.5% of semaglutide participants crossed into the diabetic A1c range vs. 12.0% on placebo
50%
Sleep apnea remission or mild
Tirzepatide vs. 14% on placebo, in adults with obesity and moderate-to-severe OSA using PAP

Heart Attack & Stroke

Cardiovascular Outcomes
SELECT · Semaglutide

In 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide 2.4 mg cut the combined risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 20% - 6.5% vs. 8.0% on placebo (HR 0.80). Death from any cause fell 19%.

Mean follow-up 39.8 months. Only non-fatal heart attack reached significance on its own; the composite endpoint is what was significant.
SUSTAIN-6 · Semaglutide

In 3,297 adults with type 2 diabetes at high cardiovascular risk, the same composite endpoint fell 26% (HR 0.74) over a median 2.1 years.

This trial also found more diabetic retinopathy complications on semaglutide (3.0% vs. 1.8%), a known caution in people with existing eye disease.
SURPASS-CVOT · Tirzepatide

In 13,299 adults with type 2 diabetes and heart disease over a median 4 years, tirzepatide 15 mg was non-inferior to dulaglutide for major cardiac events (12.2% vs. 13.1%). Death from any cause was 16% lower.

This compared tirzepatide to another active GLP-1 drug, not to placebo, and superiority for cardiac events was not demonstrated.

Kidney Protection

Renal Outcomes
FLOW · Semaglutide

In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg reduced major kidney disease events by 24% (HR 0.76) over a median 3.4 years. Cardiovascular death fell 29% and death from any cause 20%.

Kidney function declined more slowly too - annual eGFR loss was 1.16 mL/min/1.73m² less steep than placebo.
SURPASS-4 · Tirzepatide

A composite kidney endpoint was 41% lower with tirzepatide than with insulin glargine (HR 0.59), with new-onset macroalbuminuria down 59%.

Weaker evidence than FLOW: a post hoc analysis of an open-label trial against insulin, not a dedicated kidney outcomes trial.

Heart Failure Symptoms

HFpEF with Obesity
SUMMIT · Tirzepatide

In 731 adults with heart failure with preserved ejection fraction plus obesity, tirzepatide cut the risk of cardiovascular death or worsening heart failure by 38% (9.9% vs. 15.3%). Heart failure hospitalizations alone fell 56%.

Symptom scores improved 6.9 points and 6-minute walking distance improved 18 meters over placebo.
STEP-HFpEF · Semaglutide

In 529 adults with the same condition, semaglutide 2.4 mg improved symptom and physical-limitation scores by 7.8 points more than placebo and added 20.3 meters to 6-minute walking distance over 52 weeks.

Inflammation (CRP) dropped 43.5% vs. 7.3%. These were symptom and function endpoints, not deaths or hospitalizations.

Obstructive Sleep Apnea

An FDA-Approved Indication
SURMOUNT-OSA · Tirzepatide

In adults with obesity and moderate-to-severe sleep apnea, tirzepatide reduced breathing interruptions by about 25 events per hour (vs. 5 on placebo) in people not using a PAP machine, and 29 per hour (vs. 6) in people who were.

Reaching remission or mild, non-symptomatic apnea: 42% vs. 16% (no PAP) and 50% vs. 14% (on PAP), over 52 weeks.
FDA Approval · December 2024

On the strength of that trial, the FDA approved branded tirzepatide (Zepbound®) for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication ever approved for the condition.

This approval applies to the FDA-approved branded product only.
ESSENCE · Semaglutide (MASH)

In adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis, 62.9% on semaglutide 2.4 mg had their steatohepatitis resolve without worsening fibrosis at 72 weeks, vs. 34.3% on placebo.

Liver fibrosis improved in 36.8% vs. 22.4%. FDA granted accelerated approval for this use in August 2025; confirmatory data are still being collected.

Joints, Blood Pressure & Metabolic Health

Secondary Outcomes
STEP 9 · Semaglutide

In 407 adults with obesity and knee osteoarthritis, knee pain scores fell 41.7 points on semaglutide vs. 27.5 on placebo, a 14.2-point advantage, with physical function improving alongside it.

No equivalent randomized trial exists for tirzepatide in knee osteoarthritis.
SELECT · Semaglutide (secondary)

Alongside the cardiac results: waist circumference down 6.5 cm more than placebo, systolic blood pressure down 3.3 mm Hg, inflammation (CRP) down 37.8 points, and triglycerides down 15.6%.

The blood pressure and LDL effects are real but modest; the inflammation and triglyceride effects are large in relative terms.
Straight Talk

Side Effects: What Actually Happens

These are effective medications, and they come with real side effects. Most are digestive, most are mild to moderate, and most cluster around the weeks when your dose goes up. Here are the rates reported in the FDA labels of the branded products, side by side with placebo.

These rates come from the branded products, not the compounded ones. The percentages below are transcribed from the FDA prescribing information for Wegovy® and Zepbound®. The safety profile of compounded semaglutide and compounded tirzepatide has not been established in clinical trials, and it may differ - concentration, excipients and preparation are not the same. Tell your clinician about any side effect you experience, whatever this table says.

Semaglutide

Wegovy® 2.4 mg label - adults
Side effectDrugPlacebo
Nausea44%16%
Diarrhea30%16%
Vomiting24%6%
Constipation24%11%
Abdominal pain20%10%
Headache14%10%
Fatigue11%5%
Indigestion9%3%
Hair thinning3%1%
Any digestive side effect: 73% vs. 47% on placebo. 6.8% of participants stopped treatment because of a side effect, vs. 3.2% on placebo.

Tirzepatide

Zepbound® label - 15 mg dose
Side effectDrugPlacebo
Nausea28%8%
Diarrhea23%8%
Vomiting13%2%
Constipation11%5%
Abdominal pain10%5%
Indigestion10%4%
Injection-site reaction8%2%
Fatigue7%3%
Hair thinning5%1%
6.7% at the 15 mg dose stopped treatment because of a side effect, vs. 3.4% on placebo. Injection-site reactions are notably more common than with semaglutide.

Boxed warning: thyroid tumors

Both molecules carry the FDA's most serious warning class. In rodent studies they caused thyroid C-cell tumors; whether they do in humans is not known.
  • Do not use if you or a family member has ever had medullary thyroid carcinoma (MTC).
  • Do not use if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use if you've had a serious allergic reaction to semaglutide or tirzepatide.
  • Tell your clinician right away about any neck lump or swelling, trouble swallowing, shortness of breath or lasting hoarseness.

Serious risks to know about

Uncommon, but important. Call your clinician promptly if any of these appear.
  • Pancreatitis - severe, persistent stomach pain, often radiating to the back.
  • Gallbladder problems - gallstones and inflammation occur more often than weight loss alone would predict.
  • Kidney injury from dehydration, most reported cases occurred alongside vomiting or diarrhea. Fluids matter.
  • Low blood sugar - especially with insulin or a sulfonylurea. Doses often need adjusting.
  • Worsening diabetic eye disease, bowel blockage, and a mean heart-rate rise of 1-4 bpm.
  • Anesthesia risk - these drugs slow stomach emptying. Tell every surgeon and anesthesia provider before any procedure.

Who shouldn't take these

Your clinician will screen for all of this - be candid on your intake.
  • Personal or family history of medullary thyroid carcinoma, or MEN 2.
  • Pregnancy, planning pregnancy, or breastfeeding.
  • Severe gastroparesis; prior pancreatitis or symptomatic gallstones (caution).
  • Type 1 diabetes; active eating disorder; severe or unstable depression.
  • A surgery or procedure coming up under anesthesia or deep sedation.
  • Tirzepatide only: if you use oral birth control, add a non-oral or barrier method for 4 weeks after starting and after each dose increase.

How to make it easier

What experienced clinicians actually tell patients. Most side effects are manageable.
  • Titrate slowly. If a step is rough, hold where you are for another four weeks.
  • Eat smaller and slower. Stop at first fullness. Go easy on greasy food and alcohol.
  • Hydrate deliberately. Most reported kidney injury occurred alongside dehydration.
  • Protect your muscle. Aim for 20-30 g of protein per meal and resistance training 2-3× a week.
  • Stay in touch. Persistent vomiting or diarrhea is a reason to call us, not to tough it out.
Questions, Answered Honestly

Before You Get Started

Is compounded semaglutide the same thing as Ozempic or Wegovy?
It contains the same active ingredient - semaglutide. It is not the same product. Ozempic® and Wegovy® are FDA-approved medications manufactured by Novo Nordisk, reviewed for safety, effectiveness and quality. A compounded medication is prepared by a licensed pharmacy for an individual patient based on a prescription. The FDA does not review compounded medications before they are marketed, and there is no such thing as an FDA-approved generic semaglutide. If any company tells you their compounded product is "FDA-approved," that claim is false.
Then why do the clinical trial results on this page matter?
Because they tell you what the molecule does. Semaglutide and tirzepatide have been studied in tens of thousands of people. What those results cannot tell you is what a compounded preparation will do for you specifically - different formulation, different concentration, no FDA review of that particular product. We show you the evidence because you deserve to understand the science, and we label its limits for the same reason.
Which one will my clinician put me on?
That depends on your goal, medical history, budget and how you respond. Broadly: semaglutide is the more affordable entry point with the deepest research record beyond weight loss. Tirzepatide produces more weight loss on average and is the stronger choice if you also have sleep apnea or a larger goal. Many members start on semaglutide and switch later if progress stalls.
How much weight will I lose?
Nobody can honestly promise you a number. In the branded clinical trials, average weight loss was roughly 15% with semaglutide 2.4 mg at 68 weeks and 21% with tirzepatide 15 mg at 72 weeks, but those were averages across large groups on full doses, with structured diet and activity support. Some people lose more, some less, some nothing. Individual results vary and no outcome is guaranteed.
How does the $50 member discount actually work?
If you're an active OptimalMD member, $50 comes off the current market price of every version of every medication in the catalog, on every refill, not just your first. On a 4-week refill cycle, that's roughly $650 a year. At checkout, enter the email address on your membership; we verify your status instantly and apply the code.
Will this show up on my insurance or medical record?
No claim is submitted to insurance, so there is no insurance code attached to this care and no prior authorization to wait on, you pay a transparent cash price. Your clinician does keep a medical record of your care, as any licensed provider must. What you avoid is the insurance paper trail, not the medical documentation, which exists for your safety.
Do I have to inject myself?
Not necessarily. Semaglutide is available as a daily dissolvable tablet as well as a weekly injection. Tirzepatide is injection-only. That said, the weekly injections use a very fine, short needle and most members find them far easier than expected, one small injection into the fat of the abdomen or thigh, once a week.
What happens if I stop taking it?
Appetite typically returns and weight regain is common. These medications treat obesity as an ongoing condition rather than curing it - in the same way blood pressure medication works only while you take it. That's why the habits built during treatment matter: protein intake, resistance training, sleep and consistent eating patterns carry results forward. Talk to your clinician before stopping so you can taper thoughtfully.
Can I cancel?
Yes, any time, with no cancellation fee and no contract. If a medication isn't right for you, tell your care team - often the answer is a dose adjustment or a different molecule rather than stopping entirely.
Step 1 of 2

Read enough? Here's what it costs.

Every option, ordered lowest to highest, with your member price beside the market price - plus what's included at no extra charge: your consultation, your follow-ups, dose changes, and 3,900+ lab tests at $0.

From $129 per 4 weeks $50 off every refill $0 consultation $0 lab work Care coaching included No contract
See Pricing & Program Take the Health Quiz